Accord Healthcare Inc, a US-based generic pharmaceutical company, announced on Wednesday that it has added Dehydrated Alcohol Injection to its line of cardiovascular drugs.
Accord's product is AB-rated to BPI Labs' Ablysinol and is offered in 99% 5mL vials.
Dehydrated Alcohol is approved by the FDA and is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.
"The launch of Accord Healthcare's Dehydrated Alcohol Vials represents a meaningful advancement in offering a more convenient alternative to the traditional ampule market," said Chrys Kokino, Accord Healthcare US president.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology